Elucid’s Plaque-IQ™ Named “Best New Cardiology Technology Solution” in 2026 MedTech Breakthrough Awards Program

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that its Plaque-IQ arterial plaque analysis software has been selected as winner of the “Best New Cardiology Technology Solution” award in the 10^th annual MedTech Breakthrough Awards. The awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market.

Unlike other plaque analysis technologies based on subjective visual assessment, Elucid’s Plaque-IQ is the only plaque analysis technology trained and validated against objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology™ (CT-VH™), Plaque-IQ noninvasively quantifies and classifies coronary and carotid plaque and its components – including lipid rich necrotic core (LRNC) – offering direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies. By focusing on true disease biology rather than population-based risk estimates, this approach is designed to help physicians prioritize and personalize treatment for each individual patient.

“Elucid is redefining how cardiovascular disease (CVD) is identified, enabling earlier identification of disease and intervention. CVD is the leading cause of death and disability worldwide, yet many are undiagnosed until a serious event occurs, with seemingly low risk patients accounting for almost half of heart attacks. Current diagnostics miss key information on the type of plaque patients have, relying on technologies validated only against visual interpretation,” said Steve Johansson, managing director, MedTech Breakthrough. “With Plaque-IQ, there is a future where CVD is found earlier. Elucid’s solution supports physicians' understanding of patient risk to tailor medical guidance and prevent heart attack and stroke.”

Elucid CEO Kelly Huang, PhD., added, “The strongest early predictor of cardiovascular risk is atherosclerotic plaque buildup in the arteries, making early detection and targeted intervention essential to improving outcomes. Just as mammography transformed breast cancer screening and colonoscopy for colon cancer, we believe advanced cardiovascular screening can become routine preventive care. We remain committed to advancing clinically meaningful imaging analytics that support physician decision-making and help reduce the burden of and lives lost to heart attack and stroke.”

Now celebrating its 10th anniversary, the MedTech Breakthrough Awards program has spent a decade recognizing the companies driving meaningful progress and improving patient care across the global health and medical technology industry. The program spans a wide range of categories – including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices and beyond – honoring the innovations reshaping how care is delivered worldwide.

This year's program drew a record-breaking number of nominations from leading companies and startups across more than 20 countries, reflecting the growing global impact and momentum of the digital healthcare industry.

About Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary and carotid plaque buildup), the root cause of cardiovascular disease. The company’s Plaque-IQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR_CT, derived from its plaque algorithm, resulting in concordance between plaque and FFR_CT. FFR_CT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively. For more information, visit elucid.com.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507949647/en/